24 jul: Bobler fra dybet fik hammerslag på rekordpriser ved nyligt afhold..
01 aug: Mercedes CLS Shooting Brake på vej til Danmark
26-07-2012 22:51:00

Amgen 2nd-Quarter Profit Rises 8.2%; 2012 Outlook Raised

Relateret indhold
Relateret debat
06 feb - 
Jeg spurgte en ekspert, og her er, hvad han havde at si..
06 feb - 
Jeg synes, at en korrektion er helt paa sin plads og me..
05 feb - 
Amgen har en markedsvaerdi paa $135B og nu koeber de ak..

By Tess Stynes

Amgen Inc.'s (AMGN) second-quarter earnings rose 8.2% as weaker sales of the biopharmaceutical company's anemia drugs were offset by growth of other treatments.

Shares rose 4.7% to $83 in after-hours trading Thursday as adjusted earnings and revenue beat expectations and the company raised its 2012 outlook. Through the close, the stock was up about 23% this year.

For the year, the company raised its per-share earnings estimate to a range of $6.20 to $6.35 on revenue of $16.9 billion to $17.2 billion, from its prior estimates for $5.90 to $6.15 and $16.1 billion to $16.5 billion.

Amgen has been pursuing deals to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed a $1.16 billion acquisition of Micromet Inc., a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.27 billion, or $1.61 a share, up from $1.17 billion, or $1.25 a share, a year earlier. Excluding acquisition-related charges, stock-compensation expenses and other items, earnings were up at $1.83 from $1.37.

Revenue increased 13% to $4.48 billion, including 8% growth in product sales.

Analysts polled by Thomson Reuters most recently projected earnings of $1.54 a share on revenue of $4.08 billion.

Combined sales of Neulasta and Neupogen, which are used to ward off infections in patients undergoing cancer treatment, grew 2% mainly on an increase in U.S. average selling prices. Enbrel sales jumped 11%.

However, sales of anti-anemia drugs Aranesp and Epogen were down about 8% and 3%, respectively.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Second-quarter sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, saw sales increase 17% from the first quarter. Sales of Prolia, for osteoporosis in women, climbed 36% quarter to quarter.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 16:51 ET (20:51 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Vestas vinder mølleordre i USA

21-02-2018 13:57:11
Vestas har fået en ordre på 50 megawatt (MW) i USA. Ordren er på V136-3,45 MW-møllen, der er optimeret til 3,6 MW.Den mølletype har siden oktober 2017 givet Vestas en samlet ordreindgang i USA på mere end 900 MW.Det oplyser Vestas i en meddelelse.Kontrakten med kunden, der har ønsket at være anonym, omfatter levering og installation samt idriftsættelse af møllerne, og der er også en flerårig servi..

Vestas henter italiensk ordre på 57 MW - NY

21-02-2018 11:18:47
Vestas har modtaget en bestilling på vindmøller med en samlet kapacitet på 57 megawatt (MW) til et projekt i Italien.Kunden er energiselskabet E.On.Det fremgår af en meddelelse onsdag formiddag.Ordren omfatter 19 styk V112-3,0 MW-møller, og kontrakten er resultatet af et udbud over italienske vindmølleprojekter, og det såkaldte Morcone-projekt, som møllerne skal bruges til, bliver et af de største..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Vestas, Genmab og Mærsk kan komme i fokus
2
Mærsk/Sydbank: Aktionærer kan se frem til udbetaling i 2018 eller 2019
3
Vestas vinder mølleordre i USA
4
Genmab: Darzalex-salget i USA steg med 6,2 pct. i januar
5
Aktier/åbning: Genmab, Mærsk og Vestas trækker C25 i rødt

Relaterede aktiekurser

Amgen Inc 184,06 0,6% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. februar 2018 20:10:36
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180219.1 - EUROWEB6 - 2018-02-21 20:10:36 - 2018-02-21 20:10:36 - 1 - Website: OKAY